ACTA ENDOCRINOLOGICA (BUC)

Background. Prior studies examining cyclic mastalgia and sex hormones have failed to\r\nreveal any specific endocrine cause and their results of them are inconsistent.\r\nAim. To evaluate luteal hormonal levels in women with marked premenstrual mastalgia\r\nin response to toremifene.\r\nMethods. In a double-blind crossover randomization procedure after one baseline cycle,\r\n32 women were randomized to receive 20 mg toremifene, and 30 women placebo from cycle\r\nday 15 until the next menstruation for three menstrual cycles. After a wash-out cycle the women\r\nwere crossed over to receive placebo and toremifene, respectively. The luteal hormonal levels\r\nwere measured at baseline, and during the third cycle of toremifene and placebo. The study was\r\nsetup in a general practice population from two Finnish hospital districts. Serum FSH, estradiol,\r\nprogesterone, prolactin, androstenedione, total and free testosterone were measured.\r\nResults. When all the toremifene-treated cycles were compared with all the placebo\r\ncycles and with the baseline, the median estradiol levels were 0.36, 0.27 and 0.31 nmol/L,\r\nrespectively (baseline versus toremifene, P=0.005; baseline versus placebo P=0.095; and\r\ntoremifene versus placebo P<0.001). The median progesterone levels were at baseline 32.5\r\nnmol/L, during placebo 34.5 nmol/L and during toremifene 42.5 nmol/L (baseline versus\r\ntoremifene P=0.002; baseline versus placebo P=0.802; and toremifene versus placebo\r\nP=0.002). The median prolactin level was significantly higher during the toremifene cycles\r\n(268 mU/L) as compared to the baseline (222 mU/L, P=0.046). There were no significant\r\nchanges in other hormone concentrations evaluated.\r\nConclusion. Toremifene seems to have a luteotropic effect in women suffering from\r\npremenstrual mastalgia.